Treatment with rocatinlimab resulted in statistically significant and clinically meaningful improvements across clinical endpoints in adult patients with moderate to severe atopic dermatitis. These improvements included the coprimary endpoints of EASI-75 response and vIGA-AD scores of 0 or 1 compared to placebo. The ROCKET-IGNITE and ROCKET-HORIZON studies were two global, double-blind, placebo-controlled, randomized phase 3 clinical trials. Rocatinlimab had a clinically acceptable safety profile. Studies focused on efficacy and safety in patients with this skin condition. The main findings confirm significant improvements compared to placebo.